U.S. pharmaceutical company Eli Lilly plans to disclose the topline results of its phase 3 clinical trial for remternemab, a new drug candidate developed as a successor to its Alzheimer’s treatment ...

Myanmar holds second round of ‘sham elections’ amid armed conflict - Special rapporteur working with UN human rights office ...